Geographic Analysis: Market, By Application Category
According to the new market
research report “Vaccine Adjuvants Market by Product Type (Particulate,
Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous,
Intramuscular), Disease Type (Infectious, Cancer), Application (Research,
Commercial) & Application Category - Forecasts to 2021", published by MarketsandMarkets™, report provides a detailed overview of the
major drivers, restraints, challenges, opportunities, current market trends,
and strategies impacting the vaccine adjuvants market along with the estimates
and forecasts of the revenue and market share analysis.
Get 10% Free Customization on
this report @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894
The global vaccine adjuvants market
is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016
at a CAGR of 10.5% from 2016 to 2021. The major factors driving the growth of
this market are high prevalence of infectious and zoonotic diseases, increasing
focus on immunization programs by various government bodies, and growing focus
on improved and long-lasting immunization against existing and emerging
diseases.
Based on applications, the global
vaccine adjuvants market is segmented into research and commercial
applications. Research applications are expected to account for the largest
share of the market during the forecast period. Growth in this segment is
driven by factors such as increasing need for better immunization for the
increasing geriatric population and increasing government funding in research
to meet the unmet needs for safe and effective vaccine adjuvants.
On the basis of application
categories, the vaccine adjuvants market is segmented into human and veterinary
adjuvants. Adjuvants for humans are expected to account for the largest share
of the global vaccine adjuvants market in 2016 and are expected to grow at a
higher CAGR in the application category segment.

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894
The key players in the vaccine
adjuvants market include Brenntag Biosector (Denmark), CSL Limited (Australia),
SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc.
(U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories,
Inc. (U.S.), and OZ Biosciences (France).
Comments
Post a Comment